Anti-Infective Agents Market Outlook (2022-2033)

Increasing Incidence and Persistent Burden of Infectious Diseases

Infectious diseases that include COVID-19, influenza, tuberculosis, HIV, and hepatitis are still prevalent all over the world, making it necessary for healthcare systems to depend on anti-infective agents quite a bit for treating and managing those diseases. Besides, the aging of the population and the rising number of people with weaker immunity can be considered as one of the reasons for the long-term prevalence of these diseases, which in turn leads to the wider prescribing and usage of anti-infective therapies. Further, the increasing antimicrobial resistance (AMR)—with the WHO reporting hundreds of thousands of deaths every year due to drug-resistant infections—makes the market for next-generation anti-infective drugs and new treatment strategies even more demanding. The mentioned trends have resulted in the prioritization of the development of innovative drugs, diagnostics, and stewardship programs by healthcare providers and pharmaceutical companies, thus giving a continuous growth momentum to the anti-infective landscape.

Advancements In Precision Medicine and Next-Generation Therapeutics Driven by Technological Innovation and Strategic Collaborations

Pharmaceutical companies and biotech firms are following the trend of investing more and more to develop personalized and targeted anti-infective approaches, such as genomic profiling, AI-assisted drug discovery, and new therapeutic classes that would meet the requirements of drug-resistant pathogens and others. According to recent reports, a larger portion of clinical trials is being conducted on personalized treatment options, and advanced technologies like genome sequencing are becoming more accessible, thus making it easier to design patient-specific therapy. In the same way, the worldwide expansion of the pipeline with new molecules, combination therapies, and biologics is giving evidence to the industry's capability for radical advancements. Public-private partnerships, along with regulatory incentives, are the main reasons why these therapies are getting quicker development and approval processes, hence creating new revenue streams and differentiation opportunities. This evolving ecosystem creates fertile ground for growth in both developed and emerging markets as precision and next-generation anti-infective solutions gain traction.

The " Anti-Infective Agents Market Size and Forecast (2022–2033)" report provides a detailed analysis of the market covering below areas:

• Anti-infective agents market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
• Anti-infective agents market trends, as well as market dynamics such as drivers, restraints, and key opportunities
• Anti-infective agents market analysis covering key market trends, global and regional framework, major players, regulations, and recent market developments
• Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments for the anti-infective agents market
• Detailed company profiles, including SWOT analysis

The geographical scope of the anti-infective agents market report is divided into five regions: North America, Asia Pacific, Europe, Middle East & Africa, and South & Central America. The anti-infective agents market in Asia Pacific is expected to grow significantly during the forecast period.

The Asia-Pacific anti-infective agents market is segmented into China, Japan, South Korea, India, Australia, New Zealand, Indonesia, Malaysia, the Philippines, Singapore, Thailand, Vietnam, Taiwan, Bangladesh, and the Rest of Asia. The Asia-Pacific anti-infective agents market is experiencing robust growth, due to the prevalence of infectious diseases in large countries such as China, India, Indonesia, and other Southeast Asian countries being very high. This results in the need for various types of anti-infective therapies, which include antibiotics, antivirals, and antifungal treatments, and the demand is constant. These areas still report high incidence rates of diseases such as TB, hepatitis, and respiratory infections, which in turn require the use of more anti-infective medications.

Moreover, the healthcare infrastructure has been expanding and modernizing very quickly, while public and private healthcare spending has been increasing. This has led to access to diagnosis and treatment services even in remote areas, both urban and rural. In addition, the growing investment in healthcare facilities, diagnostic laboratories, and pharmaceutical manufacturing is making anti-infective agents more available and ultimately attracting market participation.

On top of that, the government and public health programs aimed at infectious disease control and immunization coverage expansion are the main reasons for the further market growth. The programs that target HIV, hepatitis, and other endemic infections help increase the use of anti-infective therapies. Along with this, the rising health awareness and the growing middle-class population with greater healthcare affordability are making Asia-Pacific one of the fastest-growing regions in the anti-infective agents market.

• The report includes qualitative and quantitative data in the Anti-Infective Agents Market across type, route of administration, distribution channel, and geography.
• The report starts with the key takeaways (chapter 2), highlighting the key trends and outlook of the anti-infective agents market.
• Chapter 3 includes the research methodology of the study.
• Chapter 4 further includes ecosystem analysis.
• Chapter 5 highlights the major industry dynamics in the anti-infective agents market, including factors that are driving the market, prevailing deterrents, potential opportunities, as well as future trends. Impact analysis of these drivers and restraints is also covered in this section.
• Chapter 6 discusses the anti-infective agents market scenario, in terms of historical market revenues, and forecast till the year 2031.
• Chapters 7 to 10 cover Anti-Infective Agents Market segments by type, route of administration, distribution channel, and geography across North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America. They cover the market revenue forecast and factors driving the market.
• Chapter 11 describes the competitive analysis along with the heat map analysis for the key players operating in the market.
• Chapter 12 describes the industry landscape analysis. It provides detailed descriptions of business activities such as market initiatives, new developments, mergers, and joint ventures globally, along with a competitive landscape.
• Chapter 13 provides detailed profiles of the major companies operating in the anti-infective agents market. Companies have been profiled on the basis of their key facts, business descriptions, products and services, financial overview, SWOT analysis, and key developments.
• Chapter 14, i.e., the appendix is inclusive of a brief overview of the company, list of abbreviations, and disclaimer.

The anti-infective agents market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. A few of the key developments in the anti-infective agents market are:

• In September 2025, Cipla Limited announced the launch of Methenamine Hippurate, a non-antibiotic treatment for patients suffering from recurrent urinary tract infections (UTIs), under the brand name HUENA. This marks a significant step forward for the company in the fight against Antimicrobial Resistance (AMR) and reinforces its commitment to antimicrobial stewardship, as it becomes the first to introduce this treatment in India.
• In December 2025, Basilea Pharmaceutica Ltd, Allschwil, a commercial-stage biopharmaceutical company, announced a partnership with Phare Bio Inc., Boston (USA), a biotech social venture that uses Artificial Intelligence (AI) to accelerate antibiotic discovery and development. Under the partnership, Phare Bio will deploy its Generative AI platform to design molecules with antibacterial properties that meet a pre-defined target product profile, which considers both unmet medical needs and the features relevant for potential commercial success of a future product.